busulfan has been researched along with cyclosporine in 104 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 33 (31.73) | 18.2507 |
| 2000's | 35 (33.65) | 29.6817 |
| 2010's | 33 (31.73) | 24.3611 |
| 2020's | 3 (2.88) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Brown, R; Stevens, M; Tiedemann, K; Vowels, M | 1 |
| Altomonte, V; Farmer, ER; Hess, AD; Jones, RJ; Santos, GW; Vogelsang, GB; Yeager, AM | 1 |
| Arseniev, L; Bähre, O; Battmer, K; Berenson, RJ; Casper, J; Diedrich, H; Jacobs, R; Kadar, JG; Kühl, J; Link, H; Poliwoda, H; Schubert, J | 1 |
| Baxter-Lowe, LA; Bunin, N; Camitta, B; Casper, J; Garbrecht, F; Hunter, J; Lawton, C; Murray, K; Pietryga, D; Truitt, R | 1 |
| Attal, M; Brousset, P; Dastugue, N; Demur, C; Duchayne, E; Rigal-Huguet, F; Robert, A; Rubie, H | 1 |
| Abla, O; Arcese, W; Boni, L; Di Bartolomeo, P; Dini, G; Iori, AP; Locatelli, F; Polchi, P; Rossetti, F; Uderzo, C | 1 |
| Abella, E; de Planque, MM; Eisenbrey, AB; Karanes, C; Lum, LG; Ratanatharathorn, V; Ravindranath, Y; Schultz, KR; Sensenbrenner, LL; Uberti, JP | 1 |
| FitzSimon, S; McCann, SR; O'Connor, M; O'Riordan, JM | 1 |
| Andreani, M; Lucarelli, G; Manna, M; Nesci, S; Tonucci, P | 1 |
| Fish, BL; Lawton, CA; Moulder, JE | 1 |
| Angelucci, E; Baronciani, D; Erer, B; Galimberti, M; Gaziev, D; Giardini, C; Lucarelli, G; Polchi, P; Rapa, S; Ripalti, M | 1 |
| Belanger, R; Boileau, J; Bonny, Y; Kassis, J; Lacombe, M; Lalonde, Y; Lavallee, R; Perreault, C; Roy, DC; von Bueltzingsloewen, A | 1 |
| Aurer, I; Bogdanić, V; Kovacević-Metelko, J; Labar, B; Maravić, N; Mrsić, M; Nemet, D; Radman, I; Zupancić-Salek, S | 1 |
| Anasetti, C; Anderson, JE; Appelbaum, FR; Bensinger, WI; Bryant, E; Buckner, CD; Chauncey, T; Clift, RA; Gooley, T; Schoch, G | 1 |
| Brugger, SA; Dieckmann, KU; Fischer, G; Geissler, K; Greinix, HT; Haas, O; Hinterberger, W; Hocker, P; Jager, U; Kalhs, P; Keil, F; Lechner, K; Linkesch, W; Mannhalter, C; Reiter, E; Schneider, B; Schwarzinger, I | 1 |
| Issaragrisil, S; Piankijakum, A; Suvatte, V; Tang-naitrisorana, Y; Visuthisakchai, S | 1 |
| Bacigalupo, A; Brinch, L; Cook, G; Domingo-Albos, A; Finke, J; Garcia-Conde, J; Gratwohl, A; Labopin, M; Lambertenghi-Deliliers, G; Lange, A; Laporte, JP; Majolino, I; Rozman, C; Schmitz, N | 1 |
| Brodsky, I; Bulova, S; Crilley, P; Marks, DI; Styler, MJ; Topolsky, D | 1 |
| Angelucci, E; Baronciani, D; Erer, B; Galimberti, M; Gaziev, D; Giardini, C; Lucarelli, G; Maiello, A; Polchi, P | 1 |
| Alonso, E; Banda, ED; Berlanga, JJ; Espanñol, I; Ferrà, C; Gallardo, D; Grañena, A; Ponce, C; Riu, C; Salar, A | 1 |
| Bertz, H; Finke, J; Mertelsmann, R; Potthoff, K | 1 |
| Grigg, A; Harun, MH; Szer, J | 1 |
| Bernaudin, F; Hernigou, P; Kuentz, M; Reinert, P; Vernant, JP | 1 |
| Hirabayashi, N; Ikeda, Y; Ishida, A; Matsuoka, S; Moriki, T; Okamoto, S; Wakui, M; Watanabe, R | 1 |
| Bandini, G; Bonini, A; Campanini, E; Mangianti, S; Motta, MR; Remiddi, C; Rizzi, S; Rondelli, D; Rosti, G; Testoni, N; Tura, S; Zuffa, E | 1 |
| Pasquini, R; Scola, RH; Werneck, LC; Zétola, VH | 1 |
| Kato, K; Kojima, S; Kondo, M; Matsuyama, T | 1 |
| Bátorová, A; Bojtárová, E; Buc, M; Demecková, E; Fehérvízyová, E; Holománová, D; Hrubisko, M; Kusiková, M; Mistrík, M; Sakalová, A | 1 |
| Bogusławska-Jaworska, J; Gorczyńska, E; Słociak, M; Toporski, J | 1 |
| Berger, C; Braumann, D; de Witt, M; Erttmann, R; Fiedler, W; Grimm, J; Horstmann, M; Hossfeld, KD; Illiger, HJ; Kabisch, H; Kröger, N; Krüger, W; Kuse, R; Schönrock, P; Stockshläder, M; Weh, HJ; Zander, AR; Zeller, W | 1 |
| Hamaguchi, M; Haneda, M; Iida, H; Kanie, T; Kodera, Y; Minami, S; Murata, M; Nishida, T; Suzuki, R; Taji, H | 1 |
| Arns da Cunha, C; Dantas da Cunha, A; de Medeiros, CR; Pasquini, R | 1 |
| Haghshenas, M; Khojasteh, HN; Ramzi, M; Zakerinia, M | 1 |
| Cantú, OG; Gómez-Almaguer, D; González-Llano, O; Jaime-Pérez, JC; Ruiz-Argüelles, A; Ruiz-Argüelles, GJ | 1 |
| Kanai, S; Kanda, Y; Makimoto, A; Mineishi, S; Miyawaki, S; Nakai, K; Niiya, H; Ohnishi, M; Ohnishi, T; Saito, A; Saito, T; Suenaga, K; Takaue, Y; Takeuchi, T; Tanosaki, R; Tobinai, K | 1 |
| Arcese, W; Cerretti, R; De Felice, L; Donato, V; Fenu, S; Guglielmi, C; Iori, A; Laurenti, L; Mengarelli, A; Micozzi, A; Romano, A; Torromeo, C | 1 |
| Bright, R; Damon, L; Eisendrath, S | 1 |
| Cavenagh, J; Chopra, R; Clark, FJ; Culligan, D; Davies, A; Fuller, S; Hunt, L; Hunter, A; Littlewood, T; Lush, R; Marks, DI; Marsh, J; Milligan, DW; Parker, A; Schey, S; Smith, GM; Towlson, K; Vandenberghe, E; Williams, CD; Yin, J | 1 |
| Berger, M; Biasin, E; Fagioli, F; Martino, S; Miniero, R; Nesi, F; Saroglia, EH; Tovo, PA | 1 |
| Flowers, ME; Leisenring, W; Maloney, DG; Maris, MB; Martin, PJ; Mielcarek, M; Sandmaier, BM; Storb, R | 1 |
| Bravo-Hernández, G; Estrada, E; Gómez-Rangel, D; López-Martínez, B; Manuel Hernández, J; Marín-López, A; Ruiz-Argüelles, GJ | 1 |
| Ackerstein, A; Bitan, M; Elad, S; Miron, S; Or, R; Resnick, IB; Samuel, S; Shapira, MY; Slavin, S; Zilberman, I | 1 |
| Issaragrisil, S; Sangruchi, T; Udomsakdi-Auewarakul, C; Visuthisakchai, S | 1 |
| Zakrzewski, JL | 1 |
| Kobayashi, K; Kobayashi, R; Mino, E; Suzuki, Y; Yamada, M; Yoshida, M | 1 |
| Fujioka, T; Ishida, Y; Numaoka, H; Omori, S; Ono, Y | 1 |
| Aulagner, G; Bertolle, V; Bleyzac, N; Martin, P | 1 |
| Andresen, S; Bolwell, B; Kalaycio, M; Kuczkowski, E; Pohlman, B; Rybicki, L; Sobecks, R | 1 |
| Arnold, R; Dörken, B; Heine, F; Le Coutre, P; Massenkeil, G; Nagy, M; Rosen, O | 1 |
| Diaconescu, R; Maloney, DG; Maris, MB; McSweeney, P; Parikh, CR; Sandmaier, BM; Schrier, RW; Sorror, ML; Storb, R; Storer, B | 1 |
| Chen, C; Chen, W; Fang, JP; Feng, HY; Feng, SW; Huang, K; Huang, SL; Li, Y; Li, Z; Liu, Y; Lu, XL; Wen, JM; Xi, J; Xiao, LL; Xie, YM; Xu, HG; Yao, XL; Ye, X; Zeng, Y; Zhang, C; Zhang, M; Zhang, WX; Zhou, DH | 1 |
| Bacher, J; Bauer, TR; Burkholder, T; Colenda, L; Gu, YC; Hai, M; Hickstein, DD; Sokolic, RA; Starost, MF; Tuschong, LM | 1 |
| Cantú-Rodríguez, OG; Gómez-Almaguer, D; Gómez-Rangel, JD; Gutiérrez-Aguirre, CH; Jaime-Pérez, JC; Rivas-Vera, S; Ruiz-Argüelles, GJ; Sobrevilla-Calvo, P; Vela-Ojeda, J | 1 |
| Furst, DE; Georges, GE; Henstorf, G; Langston, AA; Lee, J; McSweeney, PA; Nash, RA; Nelson, JL; Shulman, H; Storb, R; Sullivan, KM; Wener, M | 1 |
| Fujiwara, M; Hori, A; Kami, M; Kanda, Y; Komatsu, T; Koyama, R; Kusumi, E; Masuoka, K; Matsumura, T; Miyakoshi, S; Murashige, N; Seki, K; Tanaka, Y; Taniguchi, S; Wake, A; Yuji, K | 1 |
| Chen, J; Li, JP; Zhang, T; Zhong, J; Zhu, KE | 1 |
| Cantú-Rodríguez, OG; Gómez-Almaguer, D; Gonzalez-Llano, O; Gutierrez-Aguirre, CH; Jaime-Pérez, JC; Martinez-González, O; Morales-Toquero, A; Ruiz-Argüelles, GJ; Salazar-Riojas, R; Tarín-Arzaga, LC | 1 |
| Hara, M; Hino, M; Hori, A; Kami, M; Kanda, Y; Kim, SW; Mineishi, S; Mori, S; Ohashi, Y; Saito, AM; Suzuki, R; Takami, A; Takaue, Y; Takemoto, Y; Taniguchi, S; Yamaguchi, M; Yoshida, T | 1 |
| Bahlis, NJ; Balogh, A; Brown, CB; Chaudhry, MA; Geddes, M; Larratt, L; Quinlan, D; Russell, JA; Savoie, ML; Stewart, DA; Storek, J; Turner, AR | 1 |
| Bureo, E; Diaz de Heredia, C; Gonzalez-Vicent, M; Maldonado, MS; Martinez, A; Muñoz, A; Olivé, T; Sastre, A | 1 |
| Alimoghaddam, K; Ashouri, A; Ghaffari, H; Ghavamzadeh, A; Hadjibabaie, M; Iravani, M; Mahdavi, N; Mousavi, SA; Namdar, R; Nedaeifard, L; Shamshiri, A | 1 |
| Caballero, D; Calvo, MV; de la Cámara, R; de Oteiza, JP; Heras, I; Martino, R; Pérez-Simón, JA; Rebollo, N; San Miguel, JF; Sierra, J; Valcarcel, D | 1 |
| Amrolia, P; Ancliff, P; Bonanomi, S; Bonnanomi, S; Connor, P; Goulden, N; Hemmatpour, S; McCloskey, D; Rao, K; Veys, P; Webb, D | 1 |
| Bleyzac, N | 1 |
| Barba, P; Briones, J; Brunet, S; Delgado, J; Martino, R; Moreno, E; Piñana, JL; Sierra, J; Sureda, A; Valcárcel, D; Vega, M | 1 |
| Ashouri, A; Babaie, MH; Ghavamzadeh, A; Iravani, M; Khatami, F; Tavakoli, E | 1 |
| Bossuyt, X; Mariën, G; Uyttebroeck, A | 1 |
| Cai, Z; Han, X; He, J; Huang, H; Li, L; Lin, M; Luo, Y; Shi, J; Tan, Y; Xie, W; Ye, X; Zhao, Y; Zheng, Y | 1 |
| Baran, J; Czogała, W; Goździk, J; Krasowska-Kwiecień, A; Pituch-Noworolska, A; Skoczeń, S; Wędrychowicz, A; Wiecha, O; Zembala, M | 1 |
| Gómez-Almaguer, D; Gonzalez-Llano, O; Hernandez-Arizpe, A; Macias-Gallardo, J; Mancias-Guerra, C; Martinez-Cabriales, SA; Rodriguez-Romo, LN; Ruiz-Argüelles, GJ; Ruiz-Delgado, GJ | 1 |
| Choudhary, D; Gupta, N; Handoo, A; Katewa, S; Kharya, G; Pavecha, P; Setia, R; Sharma, SK | 1 |
| Askar, M; Mossad, S; Rybicki, L; Sobecks, R; Taimur, S; Warshawsky, I | 1 |
| Li, D; Wang, H; Wang, Z; Yan, H; Zheng, X | 1 |
| Avraham, GP; Brammer, JE; Curtin, P; Frires, R; Gajewski, J; Hayes-Lattin, B; Kovacsovics, T; Leis, JF; Maziarz, RT; Meyers, G; Nemecek, E; Palmbach, G; Slater, S; Stentz, A; Subbiah, N | 1 |
| Barba, P; Bautista, G; Cabrera, JR; Duarte, R; Esquirol, A; Fores, R; García, I; García-Marco, JA; Heras, I; Marquez-Malaver, FJ; Martino, R; Parody, R; Regidor, C; Rovira, M; Saavedra, S; Sánchez-Ortega, I; Serrano, D; Sierra, J; Vazquez, L | 1 |
| Abdel-Azim, H; Crooks, GM; Kapoor, N; Khazal, S; Kohn, DB; Mahadeo, KM; Shah, AJ; Zhao, Q | 1 |
| Du, H; Jing, Y; Lu, W; Luan, Z; Tang, X; Wu, N; Xu, S; Zhang, B | 1 |
| Chang, W; Chen, F; Fu, C; Jin, Z; Ma, X; Miao, M; Qiu, H; Ruan, C; Sun, A; Tang, X; Wu, D; Xue, S | 1 |
| Gao, ZY; Li, WD; Lu, DP; Lu, DY; Yu, XJ | 1 |
| Ding, KY; Geng, LQ; Han, YS; Liu, HL; Liu, X; Sun, ZM; Tang, BL; Tong, J; Wan, X; Wang, XB; Wang, ZY; Wu, JS; Wu, Y; Yang, HZ; Yao, W; Zhang, L; Zhang, XH; Zheng, CC; Zhu, WW; Zhu, XY | 1 |
| Chen, HR; Chen, P; Guo, Z; He, XP; Liu, XD; Lou, JX; Yang, K; Zhang, Y | 1 |
| Alyea, EP; Bashey, A; Deeg, HJ; Devine, SM; Fernandez, HF; Geller, NL; Giralt, S; Hamadani, M; Horowitz, MM; Horwitz, ME; Le-Rademacher, J; Leifer, E; Logan, BR; Maziarz, RT; Mendizabal, AM; Pasquini, MC; Porter, DL; Scott, BL; Warlick, ED; Wu, J | 1 |
| Baek, S; Choi, EJ; Choi, Y; Jeon, M; Jo, JC; Joo, YD; Kang, YA; Kang, YL; Kim, DY; Kim, H; Kim, SH; Ko, SH; Lee, JH; Lee, KH; Lee, YS; Lim, SN; Park, HS; Seol, M; Yun, SC | 1 |
| Bredius, RGM; Bresters, D; Jacobse, J; Kollen, WJW; Mensink, H; van der Stoep-Yap, MYEC | 1 |
| Adaeva, R; Banet, A; Bastos, J; Battipaglia, G; Belhocine, R; Brissot, E; de Wyngaert, ZV; Duléry, R; Giannotti, F; Isnard, F; Lapusan, S; Ledraa, T; Legrand, O; Malard, F; Médiavilla, C; Mohty, M; Paviglianiti, A; Rubio, MT; Ruggeri, A; Sestili, S; Vekhoff, A | 1 |
| Fang, BJ; Fu, YW; Gui, RR; Li, YF; Li, Z; Lyu, TX; Song, YP; Wang, J; Wei, XD; Yu, FK; Zhang, BL; Zhang, WL; Zhang, YL; Zhao, HF; Zhou, J; Zhou, KS; Zu, YL | 1 |
| Behfar, M; Ghavamzadeh, A; Hamidieh, AA; Khodayari-Namini, N; Koochakzadeh, L; Rostami, T; Salajegheh, P; Yazdanian, N | 1 |
| Ahmed Nacer, R; Ait Ouali, D; Baazizi, M; Benakli, M; Bouarab, H; Hamladji, RM; Harieche, F; Mehdid, F; Rahmoune, N; Zerkout, S | 1 |
| Akdemir, NB; Büyükaşık, Y; Demiroğlu, H; Göker, H; Haznedaroğlu, İC; Karakulak, EA; Malkan, ÜY; Özcebe, Oİ; Sayınalp, N; Tekin, F | 1 |
| Cserti-Gazdewich, C; Gerbitz, A; Hassan, M; Kim, DDH; Kumar, R; Lam, W; Law, AD; Lipton, JH; Mattsson, J; Mazzulli, T; Michelis, FV; Novitzky-Basso, I; Pasic, I; Remberger, M; Salas, MQ; Santos Carreira, A; Viswabandya, A | 1 |
3 review(s) available for busulfan and cyclosporine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Busulfan and cycosporin in bone graft children].
Topics: Bone Marrow Transplantation; Busulfan; Child; Cyclosporine; Graft Rejection; Humans; Immunosuppressive Agents | 2004 |
[Treatment of Gaucher disease with allogeneic hematopoietic stem cell transplantation: report of three cases and review of literatures].
Topics: Antilymphocyte Serum; Busulfan; Child; Child, Preschool; China; Cyclophosphamide; Cyclosporine; Disease-Free Survival; Female; Gaucher Disease; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Mycophenolic Acid; Retrospective Studies; Transplantation Conditioning; Vidarabine | 2015 |
19 trial(s) available for busulfan and cyclosporine
| Article | Year |
|---|---|
Autologous and allogeneic bone marrow transplantation for childhood acute nonlymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Cyclophosphamide; Cyclosporine; Follow-Up Studies; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Melphalan; Methotrexate; Transplantation, Autologous; Transplantation, Homologous | 1992 |
Combined transplantation of allogeneic bone marrow and CD34+ blood cells.
Topics: Adult; Antigens, CD; Antigens, CD34; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cyclosporine; Female; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Male; Methotrexate; Middle Aged; Whole-Body Irradiation | 1995 |
Intensified conditioning regimen with busulfan followed by allogeneic BMT in children with myelodysplastic syndromes.
Topics: Anemia, Refractory; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cyclosporine; Cytarabine; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Methotrexate; Myelodysplastic Syndromes; Transplantation, Homologous; Whole-Body Irradiation | 1994 |
Allogeneic bone marrow transplantation in children with acute myelogenous leukemia in first remission. Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP) and the Gruppo Italiano per il Trapianto di Midollo Osseo (GITMO).
Topics: Adolescent; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cyclosporine; Female; Graft vs Host Disease; Histocompatibility; Humans; Infant; Leukemia, Myeloid, Acute; Leukocytes; Male; Methotrexate; Multivariate Analysis; Recurrence; Remission Induction; Risk Factors; Transplantation, Homologous; Whole-Body Irradiation | 1994 |
Influence of the conditioning regimens on the incidence of mixed chimerism in thalassemic transplanted patients.
Topics: Adolescent; Adult; Antilymphocyte Serum; beta-Thalassemia; Bone Marrow; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Cell Survival; Child; Child, Preschool; Chimera; Cyclophosphamide; Cyclosporine; DNA; Graft Survival; Hematopoietic Stem Cells; Humans; Methotrexate; Polymorphism, Restriction Fragment Length | 1993 |
Allogeneic marrow transplantation in patients with chronic myeloid leukemia in chronic phase following preparation with busulfan and cyclophosphamide.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Combined Modality Therapy; Cyclophosphamide; Cyclosporine; Dose-Response Relationship, Drug; Female; Graft vs Host Disease; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Methotrexate; Middle Aged; Prednisolone; Transplantation, Homologous | 1994 |
Chemotherapy versus allogeneic bone marrow transplantation in adults with acute lymphoblastic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cyclosporine; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Male; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Survival Analysis; Transplantation, Homologous; Whole-Body Irradiation | 1993 |
Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors.
Topics: Adolescent; Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cyclosporine; Disease-Free Survival; Graft vs Host Disease; Humans; Immunosuppression Therapy; Infections; Karyotyping; Methotrexate; Methylprednisolone; Middle Aged; Myelodysplastic Syndromes; Prognosis; Recurrence; Regression Analysis; Survival Rate; Treatment Outcome; Whole-Body Irradiation | 1996 |
Variability in determination of body weight used for dosing busulphan and cyclophosphamide in adult patients: results of an international survey.
Topics: Adult; Body Weight; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cyclosporine; Dose-Response Relationship, Drug; Drug Administration Schedule; Graft vs Host Disease; Humans; Immunosuppressive Agents; Methotrexate; Transplantation Conditioning | 1997 |
High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Disease-Free Survival; Etoposide; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Leukemia, Myeloid; Male; Methotrexate; Methylprednisolone; Middle Aged; Remission Induction; Time Factors; Transplantation, Homologous | 1997 |
A new minimally ablative stem cell transplantation procedure in high-risk patients not eligible for nonmyeloablative allogeneic bone marrow transplantation.
Topics: Adult; Busulfan; Cyclosporine; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Neoplasms; Patient Selection; Pilot Projects; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2003 |
A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation.
Topics: Adult; Antineoplastic Agents, Alkylating; Bone Marrow Transplantation; Busulfan; Cyclosporine; Drug Therapy, Combination; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Incidence; Methotrexate; Middle Aged; Mycophenolic Acid; Prospective Studies; Survival Rate; Transplantation, Homologous; Treatment Outcome | 2004 |
Non-myeloablative hematopoietic stem cell transplantation is of limited value in advanced or refractory acute myeloblastic leukemia. The Mexican experience.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Mexico; Middle Aged; Recurrence; Salvage Therapy; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2007 |
Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan.
Topics: Adult; Aged; Busulfan; Cyclosporine; Drug Therapy, Combination; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lymphocyte Count; Lymphocyte Transfusion; Male; Methotrexate; Middle Aged; Myelodysplastic Syndromes; Postoperative Complications; Prospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2007 |
Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis.
Topics: Adolescent; Adult; Antineoplastic Agents; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclosporine; Drug Therapy, Combination; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Mycophenolic Acid; Myeloablative Agonists; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Survival Analysis; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2008 |
Nonmyeloablative allogeneic hematopoietic stem cell transplant for the treatment of patients with hematologic malignancies using busulfan, fludarabine, and total body irradiation conditioning is effective in an elderly and infirm population.
Topics: Aged; Antineoplastic Agents; Busulfan; Cyclosporine; Female; Frail Elderly; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Mycophenolic Acid; Prospective Studies; Siblings; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine; Whole-Body Irradiation | 2015 |
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cause of Death; Cyclosporine; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Recurrence; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation; Young Adult | 2017 |
Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Chronic Disease; Cyclophosphamide; Cyclosporine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Prospective Studies; Recurrence; Remission Induction; Siblings; Survival Analysis; Transplantation Conditioning; Transplantation, Haploidentical; Unrelated Donors; Vidarabine | 2017 |
Thiotepa, Busulfan, and Fludarabine Conditioning Regimen in T Cell-Replete HLA-Haploidentical Hematopoietic Stem Cell Transplantation.
Topics: Adolescent; Adult; Aged; Busulfan; Cyclosporine; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Male; Middle Aged; Mycophenolic Acid; Retrospective Studies; Survival Rate; T-Lymphocytes; Thiotepa; Transplantation Conditioning; Vidarabine | 2019 |
82 other study(ies) available for busulfan and cyclosporine
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Induction of cutaneous graft-versus-host disease by administration of cyclosporine to patients undergoing autologous bone marrow transplantation for acute myeloid leukemia.
Topics: Adolescent; Adult; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cyclosporine; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Skin; Skin Diseases | 1992 |
Unrelated bone marrow donor transplants for children with leukemia or myelodysplasia.
Topics: Actuarial Analysis; Adolescent; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Hepatic Veno-Occlusive Disease; Histocompatibility; Humans; Infections; Leukemia; Lung Diseases, Interstitial; Male; Methylprednisolone; Myelodysplastic Syndromes; Retrospective Studies; Risk Factors; Survival Analysis; Tissue Donors; Treatment Outcome; Whole-Body Irradiation; Wisconsin | 1995 |
Graft failure in children receiving HLA-mismatched marrow transplants with busulfan-containing regimens.
Topics: Adolescent; Adult; Age Factors; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cyclosporine; Cytarabine; Drug Therapy, Combination; Graft Rejection; Histocompatibility; HLA Antigens; Humans; Incidence; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Risk Factors; Tissue Donors | 1994 |
Retinal microvascular changes following bone marrow transplantation: the role of cyclosporine.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclosporine; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Microcirculation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retinal Vessels | 1994 |
Effect of nephrotoxic drugs on the development of radiation nephropathy after bone marrow transplantation.
Topics: Amphotericin B; Animals; Bone Marrow Transplantation; Busulfan; Cyclosporine; Gentamicins; Kidney; Kidney Diseases; Male; Rats; Whole-Body Irradiation | 1994 |
Acute graft-versus-host disease prophylaxis with methotrexate and cyclosporine after busulfan and cyclophosphamide in patients with hematologic malignancies.
Topics: Adult; Busulfan; Chronic Disease; Combined Modality Therapy; Cyclophosphamide; Cyclosporine; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Methotrexate; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Time Factors | 1993 |
Long-term leukemia-free survival after allogeneic marrow transplantation in patients with acute myelogenous leukemia.
Topics: Acute Disease; Adult; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cyclosporine; Disease-Free Survival; Female; Graft vs Host Disease; Histocompatibility; Humans; Leukemia, Myeloid; Life Tables; Male; Methotrexate; Middle Aged; Neoplasm, Residual; Remission Induction; Salvage Therapy; Survival Rate; Transplantation, Homologous; Whole-Body Irradiation | 1996 |
Study of hematopoietic progenitor cells in thalassemia after bone marrow transplantation.
Topics: beta-Thalassemia; Bone Marrow; Bone Marrow Transplantation; Busulfan; Cells, Cultured; Child; Child, Preschool; Colony-Forming Units Assay; Cyclophosphamide; Cyclosporine; Female; Graft vs Host Disease; Hematopoietic Stem Cells; Hemoglobin E; Hemoglobinuria; Homozygote; Humans; Immunosuppressive Agents; Infant; Male; Methotrexate; Reference Values | 1995 |
Transplantation of allogeneic peripheral blood progenitor cells--the EBMT experience.
Topics: Adolescent; Adult; Blood Donors; Busulfan; Child; Child, Preschool; Cyclosporine; Erythropoietin; Female; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Leukemia; Lymphoma; Lymphoproliferative Disorders; Male; Methotrexate; Middle Aged; Prednisolone; Whole-Body Irradiation | 1996 |
Unrelated donor bone marrow transplantation without T cell depletion using a chemotherapy only condition regimen. Low incidence of failed engraftment and severe acute GVHD.
Topics: Actuarial Analysis; Acute Disease; Adult; Anti-Infective Agents; Bone Marrow Transplantation; Busulfan; Cause of Death; Critical Care; Cyclophosphamide; Cyclosporine; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Granulocyte-Macrophage Colony-Stimulating Factor; Hematologic Neoplasms; Hepatic Veno-Occlusive Disease; Histocompatibility; HLA-DR Antigens; Humans; Immunosuppressive Agents; Infections; Lymphocyte Depletion; Male; Methotrexate; Middle Aged; Risk; Survival Analysis; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 1996 |
CsA-associated neurotoxicity and ineffective prophylaxis with clonazepam in patients transplanted for thalassemia major: analysis of risk factors.
Topics: Acute Disease; Adolescent; Adrenal Cortex Hormones; Adult; Anticonvulsants; beta-Thalassemia; Blood Transfusion; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Clonazepam; Coma; Combined Modality Therapy; Comorbidity; Cyclophosphamide; Cyclosporine; Female; Graft vs Host Disease; Hemosiderosis; Humans; Hypertension; Immunosuppressive Agents; Incidence; Infant; Liver Diseases; Magnesium Deficiency; Magnetic Resonance Imaging; Male; Nervous System Diseases; Retrospective Studies; Risk Factors; Seizures; Tomography, X-Ray Computed; Transplantation Conditioning; Treatment Failure; Vision Disorders | 1996 |
Neurologic complications after allogeneic bone marrow transplantation.
Topics: Bone Marrow Transplantation; Brain Abscess; Busulfan; Cerebrovascular Disorders; Cyclosporine; Encephalitis; Epilepsy, Tonic-Clonic; Graft vs Host Disease; Humans; Incidence; Magnesium Deficiency; Mycoses; Nervous System Diseases; Neuromuscular Diseases; Prednisolone; Transplantation Conditioning | 1996 |
Busulfan/cyclophosphamide in volunteer unrelated donor (VUD) BMT: excellent feasibility and low incidence of treatment-related toxicity.
Topics: Adult; Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cyclosporine; Female; Graft Survival; Graft vs Host Disease; Humans; Immunosuppressive Agents; Leukemia; Living Donors; Male; Methotrexate; Methylprednisolone; Middle Aged; Myelodysplastic Syndromes; T-Lymphocytes; Transplantation Conditioning | 1997 |
Bone-marrow transplantation in sickle-cell disease. Effect on osteonecrosis: a case report with a four-year follow-up.
Topics: Adolescent; Anemia, Hemolytic; Anemia, Sickle Cell; Bone Marrow Transplantation; Bone Regeneration; Busulfan; Cyclophosphamide; Cyclosporine; Follow-Up Studies; Humans; Humerus; Immunosuppressive Agents; Lymphatic Irradiation; Male; Osteonecrosis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 1997 |
[Severe hepatic veno-occlusive disease (VOD) which was successfully treated with supportive therapy, but subsequently developed late-recurrence].
Topics: Adult; Bone Marrow Transplantation; Busulfan; Chronic Disease; Cyclophosphamide; Cyclosporine; Graft vs Host Disease; Hepatic Veno-Occlusive Disease; Humans; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Methotrexate; Recurrence; Respiratory Distress Syndrome; Tacrolimus | 1998 |
Big BU/CY is associated with a favorable long-term outcome in patients allotransplanted for chronic myelogenous leukemia in chronic phase.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cyclosporine; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Chronic-Phase; Male; Methotrexate; Middle Aged; Prognosis; Survival Rate; Transplantation Conditioning; Transplantation, Homologous | 1998 |
[Peripheral neuropathy investigation in the early stage of bone marrow transplantation].
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Bone Marrow Transplantation; Busulfan; Child; Cross-Sectional Studies; Cyclophosphamide; Cyclosporine; Female; Humans; Immunosuppressive Agents; Incidence; Male; Methotrexate; Middle Aged; Neural Conduction; Peripheral Nervous System Diseases; Postoperative Period; Prospective Studies; Risk Factors; Time Factors | 1998 |
Late-onset hemorrhagic cystitis after hematopoietic stem cell transplantation in children.
Topics: Adolescent; Age Factors; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Cyclosporine; Cystitis; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hematuria; Humans; Immunosuppressive Agents; Incidence; Infant; Infant, Newborn; Japan; Leukemia; Male; Methylprednisolone; Risk Factors | 1998 |
Allogeneic BMT for haematological disorders: single centre experience of University Hospital Bratislava.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cyclosporine; Female; Graft vs Host Disease; Hematologic Neoplasms; Hospitals, University; Humans; Immunosuppressive Agents; Male; Middle Aged; Slovakia; Transplantation Conditioning; Transplantation, Homologous | 1998 |
High-dose chemotherapy with autologous hematopoietic progenitor cell transplantation in children with high-risk NHL and ALL-preliminary results.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Cyclosporine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Platelet Count; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Survival Rate; Transplantation, Autologous; Treatment Outcome | 1998 |
A new preconditioning regimen with melphalan, busulphan and total body irradiation followed by low-dose immunosuppressant in allogeneic haemopoietic stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclosporine; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Melphalan; Middle Aged; Tacrolimus; Whole-Body Irradiation | 1999 |
Primary renal aspergillosis: extremely uncommon presentation in patients treated with bone marrow transplantation.
Topics: Aspergillosis; Aspergillus; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cyclosporine; Fatal Outcome; Graft vs Host Disease; Humans; Immunosuppressive Agents; Kidney Diseases; Male; Middle Aged | 1999 |
Acute graft-versus-host disease in thalassaemic marrow transplantation with low-dose antithymocyte globulin.
Topics: Acute Disease; Adolescent; Anti-Inflammatory Agents; Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Drug Therapy, Combination; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Immunosuppressive Agents; Incidence; Male; Prednisolone; Severity of Illness Index; Thalassemia; Transplantation Conditioning; Treatment Outcome | 1999 |
Results of an outpatient-based stem cell allotransplant program using nonmyeloablative conditioning regimens.
Topics: Adolescent; Adult; Ambulatory Care; Busulfan; Child; Cyclophosphamide; Cyclosporine; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia; Male; Methotrexate; Middle Aged; Neural Tube Defects; Program Evaluation; Recurrence; Survival Analysis; Thalassemia; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2001 |
Successful application of nonmyeloablative transplantation for paroxysmal nocturnal hemoglobinuria.
Topics: Antilymphocyte Serum; Busulfan; Cladribine; Cyclosporine; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hemoglobinuria, Paroxysmal; Histocompatibility; Humans; Immunosuppressive Agents; Male; Middle Aged; Transplantation Conditioning; Transplantation, Homologous | 2001 |
Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Cytarabine; Disease-Free Survival; Etoposide; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Infant; Leukemia; Life Tables; Male; Methylprednisolone; Middle Aged; Premedication; Retrospective Studies; Risk; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Whole-Body Irradiation | 2002 |
A case of factitious aplastic anemia.
Topics: Adult; Anemia, Aplastic; Antilymphocyte Serum; Antineoplastic Agents, Alkylating; Busulfan; Cyclosporine; Factitious Disorders; Female; Granulocyte Colony-Stimulating Factor; Humans; Immunosuppressive Agents; Pancytopenia; Self-Injurious Behavior; Treatment Refusal | 2001 |
The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cyclosporine; Cytarabine; Data Collection; Etoposide; Female; Follow-Up Studies; Graft Enhancement, Immunologic; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Lymphocyte Transfusion; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Remission Induction; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |
Successful unrelated cord blood transplantation in two children with severe combined immunodeficiency syndrome.
Topics: Antilymphocyte Serum; Busulfan; Cyclosporine; Fetal Blood; Gastroenteritis; Graft vs Host Disease; Humans; Immunosuppressive Agents; Infant; Infant, Newborn; Salmonella Infections; Severe Combined Immunodeficiency; Stem Cell Transplantation; T-Lymphocytes; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2003 |
Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation.
Topics: Aged; Bone Marrow Transplantation; Busulfan; Cause of Death; Cyclosporine; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Incidence; Intestines; Life Tables; Liver; Male; Methotrexate; Middle Aged; Mycophenolic Acid; Organ Specificity; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Severity of Illness Index; Skin; Survival Analysis; Time Factors; Tissue Donors; Transplantation Conditioning; Vidarabine; Washington; Whole-Body Irradiation | 2003 |
Decreased transfusion requirements in patients given stem cell allografts using a non-myeloablative conditioning regimen: a single institution experience.
Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Erythrocyte Transfusion; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cell Mobilization; Humans; Male; Methotrexate; Middle Aged; Neoplasms; Peripheral Blood Stem Cell Transplantation; Platelet Transfusion; Prospective Studies; Recombinant Proteins; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2003 |
Reversal of marrow fibrosis in agnogenic myeloid metaplasia by allogeneic peripheral blood stem cell transplantation.
Topics: Busulfan; Cyclophosphamide; Cyclosporine; Female; Granulocyte Colony-Stimulating Factor; Histocompatibility; HLA Antigens; Humans; Immunosuppressive Agents; Methotrexate; Middle Aged; Peripheral Blood Stem Cell Transplantation; Primary Myelofibrosis; Transplantation, Homologous | 2003 |
Cyclosporin A-associated status epilepticus related to hematopoietic stem cell transplantation for thalassemia.
Topics: Anticonvulsants; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Disease Susceptibility; Epilepsy, Generalized; Female; Graft vs Host Disease; Hallucinations; Humans; Hypertension; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Peripheral Blood Stem Cell Transplantation; Premedication; Status Epilepticus; Thalassemia; Transplantation Conditioning | 2003 |
Umbilical cord blood stem cell transplantation from unrelated HLA-matched donor in an infant with severe congenital neutropenia.
Topics: Busulfan; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cyclosporine; DNA Fingerprinting; DNA Mutational Analysis; Granulocyte Colony-Stimulating Factor; Histocompatibility Testing; HLA Antigens; Humans; Infant; Male; Methylprednisolone; Neutropenia; Neutrophils; Recombinant Proteins; Respiratory Tract Infections; Time Factors; Tissue Donors; Tomography, X-Ray Computed; Transplantation Conditioning; Transplantation, Homologous | 2004 |
[Reduced intensity stem cell transplantation for metastatic renal cell carcinoma].
Topics: Adult; Busulfan; Carcinoma, Renal Cell; Cyclosporine; Fatal Outcome; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Kidney Neoplasms; Lung Neoplasms; Male; Methotrexate; Middle Aged; Salvage Therapy; Stem Cell Transplantation; Transplantation Chimera; Transplantation Conditioning; Vidarabine | 2004 |
Nonmyeloablative stem cell transplantation in patients with ALL and AML results in low nonrelapse mortality despite high rate of infections and GVHD.
Topics: Acute Disease; Adult; Antilymphocyte Serum; Busulfan; Contraindications; Cyclosporine; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Humans; Immunosuppressive Agents; Infection Control; Infections; Leukemia, Myeloid; Male; Middle Aged; Mycophenolic Acid; Mycoses; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Risk; Survival Rate; T-Lymphocytes; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2004 |
Comparison of ARF after myeloablative and nonmyeloablative hematopoietic cell transplantation.
Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Busulfan; Cohort Studies; Comorbidity; Cyclophosphamide; Cyclosporine; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Incidence; Male; Methotrexate; Methylprednisolone; Middle Aged; Mycophenolic Acid; Patient Selection; Postoperative Complications; Recurrence; Renal Dialysis; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2005 |
[Therapy of Duchenne muscular dystrophy with umbilical cord blood stem cell transplantation].
Topics: Alprostadil; Busulfan; Child; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Cyclosporine; Dystrophin; Ganciclovir; Humans; Male; Methylprednisolone; Muscular Dystrophy, Duchenne; Polymerase Chain Reaction; Treatment Outcome | 2005 |
Nonmyeloablative conditioning with busulfan before matched littermate bone marrow transplantation results in reversal of the disease phenotype in canine leukocyte adhesion deficiency.
Topics: Animals; Bone Marrow Transplantation; Busulfan; Cyclosporine; Dog Diseases; Dogs; Follow-Up Studies; Immunosuppressive Agents; Leukocyte-Adhesion Deficiency Syndrome; Mycophenolic Acid; Phenotype; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome | 2005 |
Allografting in patients with severe, refractory aplastic anemia using peripheral blood stem cells and a fludarabine-based conditioning regimen: the Mexican experience.
Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Disease-Free Survival; Female; Graft Rejection; Graft Survival; Graft vs Host Disease; Humans; Male; Mexico; Middle Aged; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Remission Induction; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2006 |
Allogeneic marrow transplantation in patients with severe systemic sclerosis: resolution of dermal fibrosis.
Topics: Adult; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cyclosporine; Female; Fibrosis; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Methotrexate; Myeloablative Agonists; Scleroderma, Systemic; Skin; Transplantation Conditioning; Transplantation, Homologous | 2006 |
Hepatic injury following reduced intensity unrelated cord blood transplantation for adult patients with hematological diseases.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Busulfan; Chemical and Drug Induced Liver Injury; Cholangitis; Cord Blood Stem Cell Transplantation; Cyclosporine; Female; Hematologic Diseases; Hematologic Neoplasms; Hepatic Veno-Occlusive Disease; Humans; Hyperbilirubinemia; Immunosuppressive Agents; Incidence; Infant, Newborn; Liver Diseases; Liver Function Tests; Male; Melphalan; Middle Aged; Postoperative Complications; Risk Factors; Tacrolimus; Tissue Donors; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2006 |
Clinical features and risk factors of pure red cell aplasia following major ABO-incompatible allogeneic hematopoietic stem cell transplantation.
Topics: ABO Blood-Group System; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; beta-Thalassemia; Blood Group Incompatibility; Busulfan; Child, Preschool; Cyclosporine; Epstein-Barr Virus Infections; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia; Lymphoproliferative Disorders; Male; Methotrexate; Middle Aged; Mycophenolic Acid; Plasma Exchange; Red-Cell Aplasia, Pure; Remission, Spontaneous; Retrospective Studies; Risk Factors; Rituximab; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2007 |
Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 CGY total-body irradiation, and thymoglobulin.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Antilymphocyte Serum; Antineoplastic Agents; Busulfan; Cyclosporine; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Methotrexate; Middle Aged; Myeloablative Agonists; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2007 |
Allogeneic hemopoietic stem cell transplantation (HSCT) for Wiskott-Aldrich syndrome: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON).
Topics: Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Graft vs Host Disease; Haplotypes; Hematopoietic Stem Cell Transplantation; Histocompatibility; HLA Antigens; Humans; Immunosuppressive Agents; Infant; Living Donors; Lymphocyte Depletion; Male; Melphalan; Multiple Organ Failure; Postoperative Complications; Reoperation; Retrospective Studies; Spain; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Wiskott-Aldrich Syndrome | 2007 |
Peripheral blood versus bone marrow as a source of hematopoietic stem cells for allogeneic transplantation in children with class I and II beta thalassemia major.
Topics: Acute Disease; Adolescent; beta-Thalassemia; Blood Platelets; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Histocompatibility Testing; Humans; Immunosuppressive Agents; Leukocyte Count; Male; Methotrexate; Myeloablative Agonists; Neutrophils; Peripheral Blood Stem Cell Transplantation; Recovery of Function; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous | 2008 |
Successful outcome of allo-SCT in high-risk pediatric AML using chemotherapy-only conditioning and post transplant immunotherapy.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cyclosporine; Female; Graft vs Host Disease; Humans; Immunotherapy; Infant; Leukemia, Myeloid, Acute; Male; Melphalan; Stem Cell Transplantation; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous | 2008 |
The use of pharmacokinetic models in paediatric onco-haematology: effects on clinical outcome through the examples of busulfan and cyclosporine.
Topics: Bayes Theorem; Busulfan; Child; Computer Simulation; Cyclosporine; Drug Administration Schedule; Drug Dosage Calculations; Drug Monitoring; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Immunosuppressive Agents; Models, Biological; Myeloablative Agonists; Treatment Outcome | 2008 |
Study of kidney function impairment after reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. A single-center experience.
Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Cyclosporine; Female; Glomerular Filtration Rate; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Melphalan; Methotrexate; Middle Aged; Mycophenolic Acid; Premedication; Risk Factors; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation; Young Adult | 2009 |
Comparison of peripheral blood stem cell transplant with bone marrow transplant in class 3 thalassemic patients.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Drug Therapy, Combination; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Male; Methotrexate; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Survival Rate; Thalassemia; Treatment Outcome; Young Adult | 2010 |
A transient IgE monoclonal protein in a child.
Topics: Adrenoleukodystrophy; Antibodies, Monoclonal; Busulfan; Child; Cyclosporine; Epstein-Barr Virus Infections; Hematopoietic Stem Cell Transplantation; Herpesvirus 4, Human; Humans; Immunoglobulin E; Immunosuppressive Agents; Vidarabine; Virus Activation | 2011 |
Imatinib combined with myeloablative allogeneic hematopoietic stem cell transplantation for advanced phases of chronic myeloid leukemia.
Topics: Adult; Benzamides; Blast Crisis; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cyclosporine; Disease Progression; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Methotrexate; Middle Aged; Mycophenolic Acid; Myeloablative Agonists; Piperazines; Pyrimidines; Remission Induction; Survival Rate; Transplantation Conditioning; Transplantation, Homologous | 2011 |
Allogeneic haematopoietic stem cell transplantation as therapy for chronic granulomatous disease--single centre experience.
Topics: Adolescent; Antigens, CD; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Granulomatous Disease, Chronic; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Infant; Male; Myeloablative Agonists; Risk Factors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous | 2011 |
Long-term results of placental blood allografting using reduced-intensity conditioning: multicenter experience in a developing country.
Topics: Adolescent; Adult; Aged; Busulfan; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Cyclosporine; Drug Therapy, Combination; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Immunosuppressive Agents; Infant; Kaplan-Meier Estimate; Male; Mexico; Middle Aged; Prospective Studies; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Young Adult | 2011 |
Treosulfan-thiotepa-fludarabine-based conditioning regimen for allogeneic transplantation in patients with thalassemia major: a single-center experience from north India.
Topics: Adolescent; beta-Thalassemia; Busulfan; Child; Child, Preschool; Cyclosporine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; India; Male; Myeloablative Agonists; Retrospective Studies; Survival Analysis; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2013 |
Donor T-cell chimerism and early post-transplant cytomegalovirus viremia in patients treated with myeloablative allogeneic hematopoietic stem cell transplant.
Topics: Adolescent; Adult; Aged; Busulfan; Chimerism; Cohort Studies; Cyclophosphamide; Cyclosporine; Cytomegalovirus Infections; DNA; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Incidence; Male; Methotrexate; Middle Aged; Mycophenolic Acid; Myeloablative Agonists; Proportional Hazards Models; Retrospective Studies; T-Lymphocytes; Tacrolimus; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Viremia; Young Adult | 2014 |
Good outcome of haploidentical hematopoietic SCT as a salvage therapy in children and adolescents with acquired severe aplastic anemia.
Topics: Adolescent; Anemia, Aplastic; Busulfan; Child; Child, Preschool; Cohort Studies; Cord Blood Stem Cell Transplantation; Cyclosporine; Female; Graft Survival; Graft vs Host Disease; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Male; Neutrophils; Salvage Therapy; Transplantation Conditioning; Treatment Outcome; Young Adult | 2014 |
Severe infections after single umbilical cord blood transplantation in adults with or without the co-infusion of CD34+ cells from a third-party donor: results of a multicenter study from the Grupo Español de Trasplante Hematopoyético (GETH).
Topics: Adolescent; Adult; Antigens, CD34; Bacterial Infections; Busulfan; Cohort Studies; Cord Blood Stem Cell Transplantation; Cyclosporine; Female; Granulocyte Colony-Stimulating Factor; Humans; Immunosuppressive Agents; Leukemia; Lymphoma; Male; Middle Aged; Multivariate Analysis; Mycoses; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Risk Factors; Severity of Illness Index; Thiotepa; Transplantation Conditioning; Vidarabine; Virus Diseases; Whole-Body Irradiation; Young Adult | 2015 |
Unrelated donor hematopoietic stem cell transplantation for the treatment of non-malignant genetic diseases: An alemtuzumab based regimen is associated with cure of clinical disease; earlier clearance of alemtuzumab may be associated with graft rejection.
Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal, Humanized; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Drug Administration Schedule; Female; Gene Expression; Genetic Diseases, Inborn; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Immunosuppressive Agents; Infant; Male; Methylprednisolone; Myeloablative Agonists; Pilot Projects; Survival Analysis; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors; Vidarabine | 2015 |
[Outcomes of allogeneic hematopoietic stem cell transplantation for 18 patients with paroxysmal nocturnal haemoglobinuria].
Topics: Anemia, Aplastic; Antilymphocyte Serum; Busulfan; Cyclophosphamide; Cyclosporine; Disease-Free Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hemoglobinuria, Paroxysmal; Humans; Methotrexate; Mycophenolic Acid; Retrospective Studies; Siblings; Tacrolimus; Transplantation Conditioning; Treatment Outcome; Unrelated Donors; Vidarabine | 2015 |
[Two Kinds of HLA-mismatched Allogeneic Hematopoictic Stem Cell Transplantation for Treatment of Hematologic Malignancies].
Topics: Antilymphocyte Serum; Busulfan; Cyclosporine; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Incidence; Leukemia; Mycophenolic Acid; Stem Cell Transplantation; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2016 |
[Comparison of intensified myeloablative conditioning regime without antithymocytic globulin (ATG) with myeloablative conditioning regime for single-unit unrelated umbilical cord blood transplantation in hematological malignancies].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; China; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cyclosporine; Cytarabine; Disease-Free Survival; Female; Fetal Blood; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Incidence; Male; Retrospective Studies; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2016 |
[Clinical Efficacy of Haploidentical Allo-HSCT of Reduced Intensity Preconditioning Combined with Induced Immune Tolerance after Transplantation for Severe Aplastic Anemia].
Topics: Anemia, Aplastic; Busulfan; Cyclophosphamide; Cyclosporine; Disease-Free Survival; Fathers; Hematopoietic Stem Cell Transplantation; Hematopoietic System; Humans; Immune Tolerance; Male; Methotrexate; T-Lymphocyte Subsets; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2016 |
Long-term aprepitant for nausea and vomiting associated with gastroparesis in hematopoietic stem cell transplantation.
Topics: Alemtuzumab; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Busulfan; Cyclosporine; Gastroparesis; Hematopoietic Stem Cell Transplantation; Humans; Infant; Lymphohistiocytosis, Hemophagocytic; Male; Methotrexate; Nausea; Unrelated Donors; Vidarabine; Vomiting | 2018 |
Efficacy and influencing factors of allogeneic hematopoietic stem cell transplantation in treatment of 71 children with leukemia.
Topics: Adolescent; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia; Leukemia, Myeloid, Acute; Male; Mycophenolic Acid; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Treatment Outcome | 2019 |
Outcome of allogeneic Hematopoietic Stem Cell Transplantation on Diamond-Blackfan anemia using busulfan-based myeloablative regimen.
Topics: Adolescent; Anemia, Diamond-Blackfan; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Drug Therapy, Combination; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Immunosuppressive Agents; Infusions, Intravenous; Male; Methotrexate; Prospective Studies; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2019 |
Successful Allogeneic Peripheral Blood Stem Cell Transplantation in 4 Wiskott-Aldrich Syndrome Patients.
Topics: Busulfan; Cyclosporine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Peripheral Blood Stem Cell Transplantation; Transplantation Conditioning; Wiskott-Aldrich Syndrome | 2022 |
A single-center experience of haploidentical stem cell transplantation in hematological malignancies.
Topics: Busulfan; Child; Cyclophosphamide; Cyclosporine; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Mycophenolic Acid; Prospective Studies; Retrospective Studies | 2023 |
Interaction Between High-Dose Intravenous Busulfan and Post-Transplantation Cyclophosphamide on Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Transplantation.
Topics: Adult; Antilymphocyte Serum; Busulfan; Cyclophosphamide; Cyclosporine; Cystitis; Hematopoietic Stem Cell Transplantation; Hemorrhage; Humans; Transplantation Conditioning | 2023 |